{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:59:39Z","timestamp":1787759979504,"version":"build-2784847793"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to ascertain to what extent adults with migraine value an early onset of efficacy for preventive migraine treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In placebo\u2010controlled clinical trials, treatment with eptinezumab resulted in a lower proportion of adults with migraine on the first day following infusion (day 1; 14% point\u2010reduction for chronic migraine [CM] in PROMISE\u20102 and 8% point\u2010reduction for episodic migraine [EM] in PROMISE\u20101).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with migraine completed an online preference\u2010elicitation thresholding exercise to ascertain to what extent they value not having a migraine on day 1 postdosing relative to a clinically relevant reduction in number of migraine days during the first month postdosing (\u22652 migraine\u2010free days for CM and \u22651 migraine\u2010free days for EM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and one participants (mean age, 50.6\u00a0\u00b1\u00a012.4\u00a0years; 81 [80%] women) were included. In participants with CM, 29 of 50 (58%) considered the eptinezumab\u2010generated reduction in the likelihood of migraine on day 1 postdosing to be at least as important as a clinically relevant reduction in number of migraine days the first month postdosing, whereas 37 of 50 (74%) considered a clinically relevant reduction of migraine days the first month postdosing to have a value equivalent to the eptinezumab\u2010generated reduction in the likelihood of migraine on day 1 postdosing. In participants with EM, 18 of 35 (51%) considered the eptinezumab\u2010generated reduction in the likelihood of migraine on day 1 postdosing to be at least as important as a clinically relevant reduction in migraine days the first month postdosing, whereas 24 of 35 (69%) considered a clinically relevant reduction of migraine days the first month postdosing to have a value equivalent to the eptinezumab\u2010generated reduction in the likelihood of migraine on day 1 postdosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most participants considered the reduction in the likelihood of migraine offered by eptinezumab on day 1 postdosing to be at least as important as a clinically relevant reduction in migraine days the first month postdosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14255","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T01:08:22Z","timestamp":1645405702000},"page":"374-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Patient preference for early onset of efficacy of preventive migraine treatments"],"prefix":"10.1111","volume":"62","author":[{"given":"Jessica","family":"Ailani","sequence":"first","affiliation":[{"name":"Department of Neurology Medstar Georgetown University Hospital  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Winner","sequence":"additional","affiliation":[{"name":"Palm Beach Headache Center  West Palm Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hartry","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brevig","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f8g","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Bl\u00e6del","family":"Lassen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Marsh","sequence":"additional","affiliation":[{"name":"Patient Centered Research Evidera  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Cutts","sequence":"additional","affiliation":[{"name":"Patient Centered Research Evidera Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Le Lay","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14007"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13691"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.11.004"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.1596"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1697"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0135-0"},{"key":"e_1_2_10_9_1","volume-title":"Patient Preference Information\u2014Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders","author":"Food and Drug Administration","year":"2016"},{"key":"e_1_2_10_10_1","volume-title":"Factors to Consider When Making Benefit\u2010Risk Determinations in Medical Device Premarket Approval and De Novo Classifications. Guidance for Industry and Food and Drug Administration Staff (FDA\u20102011\u2010D\u20100577)","author":"Food and Drug Administration","year":"2019"},{"key":"e_1_2_10_11_1","volume-title":"EMA Regulatory Science to 2025","author":"European Medicines Agency","year":"2020"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12142"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13498"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00757.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_10_17_1","first-page":"588","article-title":"Brief questions to identify patients with inadequate health literacy","volume":"36","author":"Chew LD","year":"2004","journal-title":"Fam Med"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2011.604383"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X0102100105"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-019-00521-3"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100507"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14255","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:25:26Z","timestamp":1762089926000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/head.14255"],"URL":"https:\/\/doi.org\/10.1111\/head.14255","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,20]]},"assertion":[{"value":"2021-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}